Avapro (Irbesartan) Patent Expiration, LOE Window & CMS Spending

Avapro (Irbesartan) by Sanofi: Off-Patent Genericized (AB Competition), 15 AB generics, $2.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSanofi
FDA Application & PathwayN020757 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors15
2024 CMS Total Public Spend$2.3M
2024 Medicare Part D Spend$2.3M
2024 Medicaid Spend$16K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.